A股異動 | 開立醫療漲超8% 獲超聲電子上消化道內窺鏡註冊證
格隆匯9月2日丨開立醫療(300633.SZ)拉昇漲8.54%,報41.83元有望突破階段高價,暫成交2.43億元,總市值177億元。公司午間公吿,超聲電子上消化道內窺鏡,已於近日獲批國家藥品監督管理局(NMPA)III類中華人民共和國醫療器械註冊證。東莞證券日前表示,維持對內窺鏡行業整體“推薦”評級。該行稱內窺鏡行業景氣度向上,本土企業研發及生產動力較強,行業未來可期。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.